Clinical trials: Fibrosis and Cirrhosis of Liver
Hepatitis C, Cirrhosis
Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics
This is a randomized, open label, single center safety and efficacy study. At least 40 cirrhotic subjects with HCV genotype 3 will receive standard of care treatment of sofosbuvir and ribavirin (SOF/RBV) as well as 60 mg daily of…
- Trial name
- NCT02304159
- Testing
- daclatasvir, Sofosbuvir, Sovaldi, Ribavirin
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Tarek I. Hassanein, M.D., FACP, FAG, AGAF
Liver Cirrhosis, Hepatocellular Carcinoma
Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation
The objective of this study is to evaluate feasibility and safety of the adoptive transfer of activated natural killer (NK) cells extracted from cadaveric donor liver graft perfusate for liver transplant recipients with…
- Conditions
- Liver Cirrhosis, Hepatocellular Carcinoma, Evidence of Liver Transplantation
- Trial name
- MIAMINK (NCT01147380)
- Testing
- Liver NK cell inoculation
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Seigo Nishida
Cirrhosis
Rifaximin Predicts the Complications of Decompensated Cirrhosis
Cirrhotic patients are predisposed to intestinal dysmotility, bacterial overgrowth, and increased intestinal permeability all leading to an increase in bacterial translocation and increased endotoxemia.
- Trial name
- NCT02074280
- Testing
- rifaximin
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Shanghai Changzheng Hospital
Cirrhosis, Periodontitis
Oral Gut Liver Axis in Cirrhosis
This will be a prospective study of cirrhotics and healthy controls comparing their oral microbiota, endotoxemia and systemic inflammation at baseline and at 30 days after clinically indicated systematic oral cleansing and…
- Conditions
- Cirrhosis, Periodontitis, Gingivitis
- Trial name
- NCT03030820
- Testing
- Dental Cleaning
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Ascites, Liver Cirrhosis
Proximal Splenic Artery Embolization (PSAE) for the Treatment of Refractory Ascites in Decompensated Cirrhosis
The purpose of this study is to learn whether a procedure called Proximal Splenic Artery Embolization (PSAE) can lower the need for repeat fluid drainage in adults with cirrhosis and a buildup of fluid in the abdomen (ascites)…
- Conditions
- Ascites, Liver Cirrhosis, Hypertension, Portal
- Trial name
- NCT07755059
- Testing
- Proximal Splenic Artery Embolization
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Liver Fibroses
The EUS ShearWave Elastography Liver Fibrosis Study
The study objective is to demonstrate the clinical performance of ShearWave Elastography (SWE) in Endoscopic Ultrasound (EUS) when compared to FibroScan for evaluation of liver fibrosis.
- Trial name
- NCT04115046
- Testing
- ShearWave Elastography (SWE) in Endoscopic Ultrasound (EUS), FibroScan, ALOKA ARIETTA 850 -
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Olympus Corporation of the Americas
Cirrhosis, Hepatic Fibrosis
Prevalence of Pain in Hospitalized Cirrhotic Patients
According to the WHO, pain is an "unpleasant sensory and emotional experience, linked to existing or potential tissue damage, or described in terms suggestive of such damage".
- Conditions
- Cirrhosis, Hepatic Fibrosis, Pain, Acute, Pain, Chronic
- Trial name
- LIVERPAIN (NCT06062108)
- Testing
- Pain evaluation
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Non-alcoholic Fatty Liver Disease, Liver Cirrhosis
Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter, multinational, dose-finding study evaluating the efficacy of three treatment doses of CC-90001 compared with placebo, in Non-alcoholic Steatohepatitis…
- Trial name
- NCT04048876
- Testing
- CC-90001
- Where
- 142 sites in United States, Australia and 8 more
- Volunteers
- 56 people
- Sponsor
- Celgene
Liver Cirrhosis
Evaluation of Accuvein in Cirrhotics Patients
The objective of this study is to evaluate the effectiveness of AccuVein AV400 to facilitate placement of peripheral intravenous catheters in cirrhotic adults by comparing the success rate of the first attempt to install a…
- Trial name
- CIRRVVUS (NCT03996135)
- Testing
- Cannulation with AccuVein AV400
- Where
- France
- Volunteers
- 280 people
- Sponsor
- University Hospital, Caen
Acute Kidney Injury, Hepatorenal Syndrome
Study of Accuracy of NGAL, a Renal Injury Biomarker, in Patients With Cirrhosis
The purpose of this study is to test the accuracy of urinary neutrophil-gelatinase associated lipocalin (NGAL) and other biomarkers (plasma renin, norepinephrine) to predict acute kidney injury (AKI) development in patients with…
- Trial name
- NCT02049125
- Where
- 4 sites in Brazil
- Volunteers
- 300 people
- Sponsor
- University of Sao Paulo
Liver Fibrosis
Development of Non-Invasive MRI Applications for Liver Fibrosis and Inflammation
Chronic liver disease is a major healthcare problem in Hong Kong and worldwide. The diagnosis of liver fibrosis and inflammation in patients with chronic liver disease has important prognostic and therapeutic implications.
- Trial name
- NCT05168982
- Where
- Hong Kong
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Liver Cirrhosis
Predictive Utility of DASIMAR as a Prognostic Biomarker in Acute-on-chronic Liver Failure (ACLF)
Patients with acute on chronic liver failure have a risk of developing multiorgan failure and a high mortality. The current scoring systems defining the outcome of patients with acute decompensation of cirrhosis fail to identify…
- Trial name
- DASIMAR (NCT01071746)
- Where
- United Kingdom
- Volunteers
- 700 people
- Sponsor
- University College London Hospitals
Hepatocellular Carcinoma, Cirrhosis
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment
This study will evaluate the usefulness of plasma proteasome levels as a tumor marker of hepatocellular carcinoma (HCC) by studying their variation following curative treatment of HCC.
- Trial name
- NCT01492127
- Testing
- Blood test
- Where
- France
- Volunteers
- 64 people
- Sponsor
- University Hospital, Montpellier
Cramps, Muscle Cramp
The RELAX Trial: Nonpharmaceutical Intervention for Nocturnal Muscle Cramps
The purpose of the study is to learn about reducing the symptoms and severity of nighttime lower body muscle cramps in patients with and without cirrhosis.
- Trial name
- RELAX (NCT05457322)
- Testing
- Behavioral intervention one, Behavioral intervention two
- Where
- 6 sites in United States
- Volunteers
- 99 people
- Sponsor
- University of Michigan
Portal Hypertension, Cirrhosis
Esophageal Capsule Endoscopy in Children
The portal hypertension (PHT) is the main complication in patients presenting with cirrhosis. It can be the direct cause of bleeding by rupture of the esophageal or gastric varices and can also contribute to the development of…
- Trial name
- PREVOCAP (NCT01551966)
- Testing
- Wireless esophageal capsule endoscopy ( PillCam Eso2)
- Where
- 7 sites in France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
Liver Cirrhosis, Biliary
Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment
This Phase 4, randomized, double-blind, placebo-controlled study will evaluate the pharmacokinetics (PK) and safety of OCA treatment in participants with PBC and moderate to severe hepatic impairment over a 48-week treatment…
- Trial name
- NCT03633227
- Testing
- Obeticholic Acid (OCA)
- Where
- 40 sites in United States, Argentina and 10 more
- Volunteers
- 22 people
- Sponsor
- Intercept Pharmaceuticals
Type 1 Diabetes, Liver Steatoses
Prevalence and Risk Factors of Metabolic-Associated Hepatic Steatosis in Individuals Living With Type 1 Diabetes
The goal of this observational cross-sectional study is to assess the prevalence and stage of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), specifically liver steatosis and fibrosis in adults aged 18 and older…
- Conditions
- Type 1 Diabetes, Liver Steatoses, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis
- Trial name
- STEA-DT1 (NCT07475962)
- Testing
- Adiposity and BMI Classification
- Volunteers
- 100 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
In this study, we aim to identify gut microbiomes specific to patients with chronic refractory liver disease and to conduct a gut-liver axis study on the pathogenesis and disease progression.
- Conditions
- Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Non-Alcoholic Fatty Liver Disease, Liver Abscess
- Trial name
- LGAS (NCT06519162)
- Where
- South Korea
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Chungnam National University Hospital
Cirrhosis
Norfloxacin Therapy for Patients With Cirrhosis and Severe Liver Failure
Patients with advanced cirrhosis have abnormal translocation of Gram-negative bacteria across the intestinal barrier and subsequent systemic inflammatory response.
- Trial name
- NORFLOCIR (NCT01037959)
- Testing
- Norfloxacin
- Where
- France
- Volunteers
- 291 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Autoimmune Liver Disease, Liver Transplant Disorder
A Study of SIPLIZUMAB in AILD and LT Patients
There is a significant unmet need for safe and effective therapeutic approaches to prevent immune-mediated graft injury and its complications in liver transplant (LT) recipients with autoimmune liver disease (AILD) including…
- Conditions
- Autoimmune Liver Disease, Liver Transplant Disorder, Autoimmune Hepatitis, Primary Sclerosing Cholangitis
- Trial name
- SET-SAIL (NCT06455280)
- Testing
- Siplizumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Elizabeth C. Verna
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.